Developer docs
API playgroundTry for free, no card

Search company profiles

Medendi

Full company profile

uuid003epnh

Namestring
Medendi
Legal namestring
Lifetime s.r.l.
Websiteurl
medendi.org
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Medendi (legal entity Lifetime s.r.l., founded circa 2019, headquartered in Modena, Italy) is a precision oncology diagnostics provider that connects cancer patients with advanced molecular testing and international oncology expertise. The company operates a direct-to-patient intake model in which a Scientific Committee of internationally affiliated oncologists, biologists, and researchers performs a free preliminary case evaluation within three days, then recommends and coordinates NGS genetic analysis (100-520 genes) and proteomic analysis (72 tumor marker proteins, exclusive in Europe per company claims). Core products include genetic analysis, proteomic analysis, hereditary risk assessment, experimental Minimal Residual Disease/recurrence-prevention analysis (in collaboration with Natera and C2i Genomics), and second-opinion referrals to centers including Memorial Sloan Kettering and Harvard Clinic. Diagnostic wet-lab work is executed through partner laboratories in the USA, Germany, and Italy rather than in Medendi-owned facilities.

Medendi's revenue model is professional services on a pay-as-you-go basis: the preliminary Scientific Committee evaluation is free, while the downstream diagnostic analyses are paid out-of-pocket by patients because these services are not reimbursed by the Italian National Health Service. Pricing is not publicly disclosed and is provided on a case-by-case quote basis. The company supplements its direct-to-patient channel with enterprise-style services to oncologists and private healthcare facilities, who receive diagnostic reports and therapeutic recommendations they can integrate into patient care. Marketing relies primarily on website content, organic social (Facebook, Twitter), and contact-form-driven lead capture.

The company is privately held with 1-10 employees and has raised 1.4 million euros in a February 2023 seed round (equity and debt) from a mix of strategic and individual investors. It maintains a wholly-owned US subsidiary, Medendi Inc., in New York City, and operates without a parent company. The leadership team consists of co-founders Giorgio Pasetto (Managing Director), Maurizio Scaltriti (Scientific Committee Coordinator; concurrently VP of Translational Medicine at AstraZeneca), and Gianmarco Molinari (CMO).

Short descriptiontext

Medendi is an Italy-based precision oncology diagnostics company that connects cancer patients with NGS genetic and proprietary proteomic tumor analysis, interpreted by an international Scientific Committee, on a direct-pay basis not reimbursed by the Italian NHS.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersModena, Italy
HQ citystring
Modena
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology diagnostics, molecular cancer diagnostics, genetic tumor analysis, proteomic tumor profiling, cancer second opinion
Industry4 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Precision Oncology Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Services
TypeProfessional Services
Description

Private diagnostic services including genetic and proteomic analysis for oncology patients. Services are paid by patients as they are not covered by the Italian National Health Service. Initial evaluation by the Scientific Committee is provided free of charge.

medendi.org
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details2 tiers
1Free preliminary evaluation
ModelOtherBilling cadencePay-as-you-go
Notes

The Scientific Committee evaluates each case to determine if genetic and/or proteomic analysis is recommended. This evaluation is delivered within 3 days and is completely free.

medendi.org
2Diagnostic analysis services
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed. Services include genetic analysis, proteomic analysis, hereditary risk analysis, MRD analysis, and second opinion consultations. Patients contact Medendi for cost information.

medendi.org
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Medendi provides advanced molecular diagnostic services for cancer patients, including Next Generation Sequencing (NGS) genetic analysis of 100-520 tumor genes and exclusive-in-Europe proteomic analysis of 72 tumor protein markers. Results are interpreted by an international Scientific Committee of oncologists and researchers who deliver personalized therapeutic recommendations, including access to clinical trials, off-label drugs, and compassionate use therapies, along with hereditary risk and minimal residual disease (MRD) testing and second opinion consultations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Identification of therapeutic options not previously considered by treating oncologists
+2 more records
Product overview1 text field

Medendi provides advanced molecular diagnostics for precision oncology, offering genetic analysis (NGS sequencing of 100-520 genes) and exclusive proteomic analysis (72 protein tumor markers) as core diagnostic services. These are complemented by hereditary risk analysis, experimental MRD/recurrence prevention (in collaboration with Natera), and second opinion services. The company integrates with international laboratories and collaborates with leading oncological centers worldwide to deliver personalized diagnostic reports and therapeutic recommendations to patients and their treating oncologists.

Product and service4 records
1Analisi Genetica (Genetic Analysis)
CategoryCore Diagnostic Service
Description

Next Generation Sequencing (NGS) analysis of 100 to 520 genes on tumor DNA/RNA to identify genetic alterations useful for therapeutic strategy, including clinical trials and compassionate use drugs. Results delivered as a report for both patient and treating oncologist.

2Analisi Proteomica (Proteomic Analysis)
CategoryCore Diagnostic Service
Description

Proteomic analysis examining 72 tumor marker proteins to identify drug resistance or sensitivity patterns not detectable by genetic analysis alone, supporting oncologists in selecting optimal therapy. Can be used standalone or combined with genetic analysis.

3Analisi del Rischio Ereditario (Hereditary Risk Analysis)
CategoryAdd-on Diagnostic Service
Description

Germline DNA mutation analysis to evaluate hereditary cancer risk for family members of patients diagnosed with hereditary-related cancer pathologies.

4Prevenzione Recidive / MRD (Minimal Residual Disease / Recurrence Prevention)
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or Integration
Description

Collaboration for Minimal Residual Disease (MRD) analysis using circulating tumor DNA sequencing. Medendi implements this experimental protocol in Italy, creating a molecular fingerprint of the tumor from the most recent biopsy sample, followed by recurring liquid biopsy analyses.

Strategic tierCoreTypeTechnology or Integration
Description

Collaboration for Minimal Residual Disease (MRD) analysis - experimental protocol for early detection of cancer recurrence through liquid biopsies and genetic analysis comparing circulating DNA with tumor molecular fingerprint.

3Specialized laboratories (USA, Germany, Italy)
Strategic tierCoreTypeTechnology or Integration
Description

External specialized laboratories conduct the actual genetic and proteomic analyses. These are not Medendi facilities but certified laboratory partners.

medendi.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

For second opinion services, Medendi can refer cases to this center of excellence in the United States. Several Scientific Committee members are affiliated with MSKCC.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

For second opinion services, Medendi can refer cases to Harvard Clinic for highly qualified medical opinions.

6Various ecosystem partners
Strategic tierCoreTypeOthers
Description

Medendi operates in synergy with companies of various sizes in multiple contexts: laboratories, AI and bioinformatics, biochemistry, logistics, clinics, and associations to deliver comprehensive oncology diagnostic services.

medendi.org
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major molecular diagnostics company (Cologuard, Oncotype DX) expanding into oncology therapy selection and MRD. Overlaps with Medendi's cancer diagnostic positioning but operates as a broad public company with diversified product lines.

2Tempus
TypeDirect peer
Description

AI-powered precision medicine company providing NGS tumor profiling (Tempus xT) and multi-omic analysis with clinical interpretation. Competes in the same patient and oncologist-facing precision oncology workflow that Medendi targets.

TypeDirect peer
Description

Roche-owned leader in comprehensive genomic profiling (NGS tumor testing) for oncology, offering assays such as FoundationOne CDx that are directly comparable to Medendi's genetic analysis service. Operates at much larger scale in the US/EU and is the primary reference point for NGS-based precision oncology.

TypeDirect peer
Description

Offers MI Profile and other multi-omic tumor profiling (DNA, RNA, proteomics) with expert molecular tumor board interpretation — directly overlapping Medendi's combined NGS + proteomic + Scientific Committee value proposition.

TypeDirect peer
Description

Provider of Signatera tumor-informed MRD testing — both a Medendi partner and a competitive peer offering similar ctDNA-based recurrence monitoring services to oncologists and patients.

TypeDirect peer
Description

Specializes in liquid biopsy and ctDNA-based MRD/recurrence monitoring (Guardant Reveal, Guardant360), directly competing with Medendi's Natera/C2i-based MRD offering for cancer recurrence surveillance.

TypeEmerging player
Description

Germany-based precision oncology company offering molecular tumor profiling with integrated clinical decision support — comparable European-scale peer with a similar focus on therapy recommendation software layered on genomic data.

TypeDirect peer
Description

Belgium-based precision oncology company offering NGS tumor profiling (OncoDNA, OncoKDM) combined with expert molecular tumor board interpretation for European patients — the closest European-headquartered competitor to Medendi.

TypeBroad incumbent
Description

Large US oncology-focused clinical laboratory offering comprehensive molecular testing including NGS, liquid biopsy, and pathology services. Competes with Medendi across most of its diagnostic menu but at substantially greater scale and with hospital system contracts.

10Perthera
TypeEmerging player
Description

US precision oncology company combining multi-omic tumor profiling with an expert molecular tumor board to deliver ranked therapy and clinical trial recommendations — highly comparable to Medendi's NGS + Scientific Committee model at a similar scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medendi

Precision Oncology Diagnosticsmedendi.org

Medendi is an Italy-based precision oncology diagnostics company that connects cancer patients with NGS genetic and proprietary proteomic tumor analysis, interpreted by an international Scientific Committee, on a direct-pay basis not reimbursed by the Italian NHS.

What Medendi does

Medendi (legal entity Lifetime s.r.l., founded circa 2019, headquartered in Modena, Italy) is a precision oncology diagnostics provider that connects cancer patients with advanced molecular testing and international oncology expertise. The company operates a direct-to-patient intake model in which a Scientific Committee of internationally affiliated oncologists, biologists, and researchers performs a free preliminary case evaluation within three days, then recommends and coordinates NGS genetic analysis (100-520 genes) and proteomic analysis (72 tumor marker proteins, exclusive in Europe per company claims). Core products include genetic analysis, proteomic analysis, hereditary risk assessment, experimental Minimal Residual Disease/recurrence-prevention analysis (in collaboration with Natera and C2i Genomics), and second-opinion referrals to centers including Memorial Sloan Kettering and Harvard Clinic. Diagnostic wet-lab work is executed through partner laboratories in the USA, Germany, and Italy rather than in Medendi-owned facilities.

Medendi's revenue model is professional services on a pay-as-you-go basis: the preliminary Scientific Committee evaluation is free, while the downstream diagnostic analyses are paid out-of-pocket by patients because these services are not reimbursed by the Italian National Health Service. Pricing is not publicly disclosed and is provided on a case-by-case quote basis. The company supplements its direct-to-patient channel with enterprise-style services to oncologists and private healthcare facilities, who receive diagnostic reports and therapeutic recommendations they can integrate into patient care. Marketing relies primarily on website content, organic social (Facebook, Twitter), and contact-form-driven lead capture.

The company is privately held with 1-10 employees and has raised 1.4 million euros in a February 2023 seed round (equity and debt) from a mix of strategic and individual investors. It maintains a wholly-owned US subsidiary, Medendi Inc., in New York City, and operates without a parent company. The leadership team consists of co-founders Giorgio Pasetto (Managing Director), Maurizio Scaltriti (Scientific Committee Coordinator; concurrently VP of Translational Medicine at AstraZeneca), and Gianmarco Molinari (CMO).

Medendi firmographics

Firmographics
Name
Medendi
Legal name
Lifetime s.r.l.
Website
https://medendi.org
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Medendi is an Italy-based precision oncology diagnostics company that connects cancer patients with NGS genetic and proprietary proteomic tumor analysis, interpreted by an international Scientific Committee, on a direct-pay basis not reimbursed by the Italian NHS.
Ownership category
akta.pro rank

Medendi industry classification

Industry
Product category
Precision Oncology Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services

Keywords

  • Precision oncology diagnostics
  • Molecular cancer diagnostics
  • Genetic tumor analysis
  • Proteomic tumor profiling
  • Cancer second opinion

Where Medendi is headquartered

Location

Headquarters

HQ city
Modena
HQ country
Italy
HQ region
Europe

Offices2 records

Markets served

Medendi business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Diagnostic Services: Private diagnostic services including genetic and proteomic analysis for oncology patients. Services are paid by patients as they are not covered by the Italian National Health Service. Initial evaluation by the Scientific Committee is provided free of charge.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goFree preliminary evaluation
OtherPay-as-you-goDiagnostic analysis services

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Medendi product offering

Product offering

Core offering

Medendi provides advanced molecular diagnostic services for cancer patients, including Next Generation Sequencing (NGS) genetic analysis of 100-520 tumor genes and exclusive-in-Europe proteomic analysis of 72 tumor protein markers. Results are interpreted by an international Scientific Committee of oncologists and researchers who deliver personalized therapeutic recommendations, including access to clinical trials, off-label drugs, and compassionate use therapies, along with hereditary risk and minimal residual disease (MRD) testing and second opinion consultations.

Product overview

Medendi provides advanced molecular diagnostics for precision oncology, offering genetic analysis (NGS sequencing of 100-520 genes) and exclusive proteomic analysis (72 protein tumor markers) as core diagnostic services. These are complemented by hereditary risk analysis, experimental MRD/recurrence prevention (in collaboration with Natera), and second opinion services. The company integrates with international laboratories and collaborates with leading oncological centers worldwide to deliver personalized diagnostic reports and therapeutic recommendations to patients and their treating oncologists.

Differentiator

Problem solved

Functional benefit

Products and services

  • Analisi Genetica (Genetic Analysis) Next Generation Sequencing (NGS) analysis of 100 to 520 genes on tumor DNA/RNA to identify genetic alterations useful for therapeutic strategy, including clinical trials and compassionate use drugs. Results delivered as a report for both patient and treating oncologist.
  • Analisi Proteomica (Proteomic Analysis) Proteomic analysis examining 72 tumor marker proteins to identify drug resistance or sensitivity patterns not detectable by genetic analysis alone, supporting oncologists in selecting optimal therapy. Can be used standalone or combined with genetic analysis.
  • Analisi del Rischio Ereditario (Hereditary Risk Analysis) Germline DNA mutation analysis to evaluate hereditary cancer risk for family members of patients diagnosed with hereditary-related cancer pathologies.
  • Prevenzione Recidive / MRD (Minimal Residual Disease / Recurrence Prevention)

Quantifiable outcome

  • Identification of therapeutic options not previously considered by treating oncologists
  • +2 more outcomes

Companies that use Medendi

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Medendi technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability1 record

Feature3 records

Medendi partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • NateracoreTechnology or IntegrationCollaboration for Minimal Residual Disease (MRD) analysis using circulating tumor DNA sequencing. Medendi implements this experimental protocol in Italy, creating a molecular fingerprint of the tumor from the most recent biopsy sample, followed by recurring liquid biopsy analyses.
  • C2i GenomicscoreTechnology or IntegrationCollaboration for Minimal Residual Disease (MRD) analysis - experimental protocol for early detection of cancer recurrence through liquid biopsies and genetic analysis comparing circulating DNA with tumor molecular fingerprint.
  • Specialized laboratories (USA, Germany, Italy)coreTechnology or IntegrationExternal specialized laboratories conduct the actual genetic and proteomic analyses. These are not Medendi facilities but certified laboratory partners.
  • Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerFor second opinion services, Medendi can refer cases to this center of excellence in the United States. Several Scientific Committee members are affiliated with MSKCC.
  • Harvard CliniccoreStrategic or Co-development PartnerFor second opinion services, Medendi can refer cases to Harvard Clinic for highly qualified medical opinions.
  • Various ecosystem partnerscoreOthersMedendi operates in synergy with companies of various sizes in multiple contexts: laboratories, AI and bioinformatics, biochemistry, logistics, clinics, and associations to deliver comprehensive oncology diagnostic services.

Scale indicators1 record

Recent moves7 records

Expansion highlights5 records

Medendi competitors and assessment

Company assessment

Broad incumbents

  • Exact Sciences: Major molecular diagnostics company (Cologuard, Oncotype DX) expanding into oncology therapy selection and MRD. Overlaps with Medendi's cancer diagnostic positioning but operates as a broad public company with diversified product lines.
  • NeoGenomics: Large US oncology-focused clinical laboratory offering comprehensive molecular testing including NGS, liquid biopsy, and pathology services. Competes with Medendi across most of its diagnostic menu but at substantially greater scale and with hospital system contracts.

Direct peers

  • Tempus: AI-powered precision medicine company providing NGS tumor profiling (Tempus xT) and multi-omic analysis with clinical interpretation. Competes in the same patient and oncologist-facing precision oncology workflow that Medendi targets.
  • Foundation Medicine: Roche-owned leader in comprehensive genomic profiling (NGS tumor testing) for oncology, offering assays such as FoundationOne CDx that are directly comparable to Medendi's genetic analysis service. Operates at much larger scale in the US/EU and is the primary reference point for NGS-based precision oncology.
  • Caris Life Sciences: Offers MI Profile and other multi-omic tumor profiling (DNA, RNA, proteomics) with expert molecular tumor board interpretation — directly overlapping Medendi's combined NGS + proteomic + Scientific Committee value proposition.
  • Natera: Provider of Signatera tumor-informed MRD testing — both a Medendi partner and a competitive peer offering similar ctDNA-based recurrence monitoring services to oncologists and patients.
  • Guardant Health: Specializes in liquid biopsy and ctDNA-based MRD/recurrence monitoring (Guardant Reveal, Guardant360), directly competing with Medendi's Natera/C2i-based MRD offering for cancer recurrence surveillance.
  • OncoDNA: Belgium-based precision oncology company offering NGS tumor profiling (OncoDNA, OncoKDM) combined with expert molecular tumor board interpretation for European patients — the closest European-headquartered competitor to Medendi.

Emerging players

  • MolecularHealth: Germany-based precision oncology company offering molecular tumor profiling with integrated clinical decision support — comparable European-scale peer with a similar focus on therapy recommendation software layered on genomic data.
  • Perthera: US precision oncology company combining multi-omic tumor profiling with an expert molecular tumor board to deliver ranked therapy and clinical trial recommendations — highly comparable to Medendi's NGS + Scientific Committee model at a similar scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Medendi social profiles

Digital presence

Medendi financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medendi leadership team

Management profile

Number of profiles

Profiles3 records

Medendi subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Medendi funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medendi M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medendi

What does Medendi do?

Medendi provides advanced molecular diagnostic services for cancer patients, including Next Generation Sequencing (NGS) genetic analysis of 100-520 tumor genes and exclusive-in-Europe proteomic analysis of 72 tumor protein markers. Results are interpreted by an international Scientific Committee of oncologists and researchers who deliver personalized therapeutic recommendations, including access to clinical trials, off-label drugs, and compassionate use therapies, along with hereditary risk and minimal residual disease (MRD) testing and second opinion consultations.

Is Medendi a public or private company?

Medendi is a private company. It is classified as venture growth investor backed and is currently operating.

When was Medendi founded?

Medendi was founded in 2019. It employs 1 to 10 people.

Where is Medendi based?

Medendi is headquartered in Modena, Italy, in the Europe region.

How does Medendi make money?

One revenue line is on record: diagnostic Services.

Who are Medendi's main competitors?

Broad incumbents on record are Exact Sciences and NeoGenomics. Direct peers are Tempus, Foundation Medicine, Caris Life Sciences, Natera, Guardant Health and OncoDNA. Emerging players are MolecularHealth and Perthera.

Does Medendi have an API?

No public API is recorded for Medendi.

What industry is Medendi in?

Medendi's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAANAA, Genomic Profiling & Sequencing-Based Precision Medicine. Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales